Samil Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Samil Pharmaceutical Co., Ltd.
BBB National Programs’ appeals panel decision “includes factual and substantive inaccuracies, is not in accordance with NARB procedures, and misstates Colgate’s positions and arguments,” Colgate says. Panel upheld findings agreeing with P&G’s challenge of “removes 10 years of yellow stains” claim.
Colgate is “not in a hurry” to make deals with valuations high for businesses it would target, says CEO Noel Wallace. Increasing commodity costs and rising inflation have the company prioritizing growth on existing businesses.
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
US consumer health sales jumped 6.7% in 2020 in stores, a reversal of recent years as consumers move away from private label, “on-the-go” and natural oral care during the pandemic, IRI data show.
- Generic Drugs
- OTC, Consumer